Literature DB >> 24253040

Proteinase-activated receptor-2 transactivation of epidermal growth factor receptor and transforming growth factor-β receptor signaling pathways contributes to renal fibrosis.

Hyunjae Chung1, Rithwik Ramachandran, Morley D Hollenberg, Daniel A Muruve.   

Abstract

Chronic kidney diseases cause significant morbidity and mortality in the population. During renal injury, kidney-localized proteinases can signal by cleaving and activating proteinase-activated receptor-2 (PAR2), a G-protein-coupled receptor involved in inflammation and fibrosis that is highly expressed in renal tubular cells. Following unilateral ureteric obstruction, PAR2-deficient mice displayed reduced renal tubular injury, fibrosis, collagen synthesis, connective tissue growth factor (CTGF), and α-smooth muscle actin gene expression at 7 days, compared with wild-type controls. In human proximal tubular epithelial cells in vitro, PAR2 stimulation with PAR2-activating peptide (PAR2-AP) alone significantly up-regulated the expression of CTGF, a potent profibrotic cytokine. The induction of CTGF by PAR2-AP was synergistically increased when combined with transforming growth factor-β (TGF-β). Consistent with these findings, treating human proximal tubular epithelial cells with PAR2-AP induced Smad2/3 phosphorylation in the canonical TGF-β signaling pathway. The Smad2 phosphorylation and CTGF induction required signaling via both the TGFβ-receptor and EGF receptor suggesting that PAR2 utilizes transactivation mechanisms to initiate fibrogenic signaling. Taken together, our data support the hypothesis that PAR2 synergizes with the TGFβ signaling pathway to contribute to renal injury and fibrosis.

Entities:  

Keywords:  Epidermal Growth Factor Receptor (EGFR); Fibrosis; Kidney; PAR2; Receptors; Transforming Growth Factor β (TGFβ)

Mesh:

Substances:

Year:  2013        PMID: 24253040      PMCID: PMC3873584          DOI: 10.1074/jbc.M113.492793

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

Review 1.  It's a Smad world: regulation of TGF-beta signaling in the kidney.

Authors:  H William Schnaper; Tomoko Hayashida; Anne-Christine Poncelet
Journal:  J Am Soc Nephrol       Date:  2002-04       Impact factor: 10.121

2.  Renal proteinase-activated receptor 2, a new actor in the control of blood pressure and plasma potassium level.

Authors:  Luciana Morla; Gaëlle Brideau; Marc Fila; Gilles Crambert; Lydie Cheval; Pascal Houillier; Sureshkrishna Ramakrishnan; Martine Imbert-Teboul; Alain Doucet
Journal:  J Biol Chem       Date:  2013-02-19       Impact factor: 5.157

3.  Protective effect of urinary trypsin inhibitor on the development of radiation-induced lung fibrosis in mice.

Authors:  Hiroyuki Katoh; Hitoshi Ishikawa; Masatoshi Hasegawa; Yukari Yoshida; Yoshiyuki Suzuki; Tatsuya Ohno; Takeo Takahashi; Takashi Nakano
Journal:  J Radiat Res       Date:  2010-03-09       Impact factor: 2.724

4.  Thrombin stimulation of proteoglycan synthesis in vascular smooth muscle is mediated by protease-activated receptor-1 transactivation of the transforming growth factor beta type I receptor.

Authors:  Micah L Burch; Mandy L Ballinger; Sundy N Y Yang; Robel Getachew; Catherine Itman; Kate Loveland; Narin Osman; Peter J Little
Journal:  J Biol Chem       Date:  2010-06-22       Impact factor: 5.157

5.  Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta.

Authors:  M Okuno; K Akita; H Moriwaki; N Kawada; K Ikeda; K Kaneda; Y Suzuki; S Kojima
Journal:  Gastroenterology       Date:  2001-06       Impact factor: 22.682

Review 6.  EGFR transactivation in the regulation of SMC function.

Authors:  A Kalmes; G Daum; A W Clowes
Journal:  Ann N Y Acad Sci       Date:  2001-12       Impact factor: 5.691

7.  Incidence and outcomes in acute kidney injury: a comprehensive population-based study.

Authors:  Tariq Ali; Izhar Khan; William Simpson; Gordon Prescott; John Townend; William Smith; Alison Macleod
Journal:  J Am Soc Nephrol       Date:  2007-02-21       Impact factor: 10.121

8.  Protease-activated receptor-2 expression in IgA nephropathy: a potential role in the pathogenesis of interstitial fibrosis.

Authors:  Giuseppe Grandaliano; Paola Pontrelli; Giuseppina Cerullo; Raffaella Monno; Elena Ranieri; Michele Ursi; Antonella Loverre; Loreto Gesualdo; Francesco P Schena
Journal:  J Am Soc Nephrol       Date:  2003-08       Impact factor: 10.121

9.  Proinflammatory and proliferative responses of human proximal tubule cells to PAR-2 activation.

Authors:  David A Vesey; Wade A Kruger; Philip Poronnik; Glenda C Gobé; David W Johnson
Journal:  Am J Physiol Renal Physiol       Date:  2007-08-15

10.  Proliferative action of mast-cell tryptase is mediated by PAR2, COX2, prostaglandins, and PPARgamma : Possible relevance to human fibrotic disorders.

Authors:  Mónica B Frungieri; Stephan Weidinger; Viktor Meineke; Frank M Köhn; Artur Mayerhofer
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-23       Impact factor: 11.205

View more
  33 in total

1.  Cathepsin S-Dependent Protease-Activated Receptor-2 Activation: A New Mechanism of Endothelial Dysfunction.

Authors:  David J Nikolic-Paterson
Journal:  J Am Soc Nephrol       Date:  2015-11-20       Impact factor: 10.121

Review 2.  G Protein Coupled Receptor-mediated Transactivation of Extracellular Proteases.

Authors:  Allison E Schafer; Burns C Blaxall
Journal:  J Cardiovasc Pharmacol       Date:  2017-07       Impact factor: 3.105

3.  Proteolytic activation of the human epithelial sodium channel by trypsin IV and trypsin I involves distinct cleavage sites.

Authors:  Silke Haerteis; Annabel Krappitz; Matteus Krappitz; Jane E Murphy; Marko Bertog; Bettina Krueger; Regina Nacken; Hyunjae Chung; Morley D Hollenberg; Wolfgang Knecht; Nigel W Bunnett; Christoph Korbmacher
Journal:  J Biol Chem       Date:  2014-05-19       Impact factor: 5.157

4.  H3K27me3 dynamics dictate evolving uterine states in pregnancy and parturition.

Authors:  Patrice Nancy; Johan Siewiera; Gabrielle Rizzuto; Elisa Tagliani; Ivan Osokine; Priyanka Manandhar; Igor Dolgalev; Caterina Clementi; Aristotelis Tsirigos; Adrian Erlebacher
Journal:  J Clin Invest       Date:  2017-11-27       Impact factor: 14.808

5.  Pharmacological Targeting of Protease-Activated Receptor 2 Affords Protection from Bleomycin-Induced Pulmonary Fibrosis.

Authors:  Cong Lin; Jan von der Thüsen; Joost Daalhuisen; Marieke ten Brink; Bruno Crestani; Tom van der Poll; Keren Borensztajn; C Arnold Spek
Journal:  Mol Med       Date:  2015-06-29       Impact factor: 6.354

6.  EGF receptor deletion in podocytes attenuates diabetic nephropathy.

Authors:  Jianchun Chen; Jian-Kang Chen; Raymond C Harris
Journal:  J Am Soc Nephrol       Date:  2014-09-03       Impact factor: 10.121

Review 7.  Integrating the GPCR transactivation-dependent and biased signalling paradigms in the context of PAR1 signalling.

Authors:  P J Little; M D Hollenberg; D Kamato; W Thomas; J Chen; T Wang; W Zheng; N Osman
Journal:  Br J Pharmacol       Date:  2016-02-16       Impact factor: 8.739

8.  Membrane-anchored Serine Protease Matriptase Is a Trigger of Pulmonary Fibrogenesis.

Authors:  Olivier Bardou; Awen Menou; Charlène François; Jan Willem Duitman; Jan H von der Thüsen; Raphaël Borie; Katiuchia Uzzun Sales; Kathrin Mutze; Yves Castier; Edouard Sage; Ligong Liu; Thomas H Bugge; David P Fairlie; Mélanie Königshoff; Bruno Crestani; Keren S Borensztajn
Journal:  Am J Respir Crit Care Med       Date:  2016-04-15       Impact factor: 21.405

Review 9.  The emerging role of coagulation proteases in kidney disease.

Authors:  Thati Madhusudhan; Bryce A Kerlin; Berend Isermann
Journal:  Nat Rev Nephrol       Date:  2015-11-23       Impact factor: 28.314

10.  Targeting Liver Fibrosis with a Cell-penetrating Protease-activated Receptor-2 (PAR2) Pepducin.

Authors:  Andrew M Shearer; Rajashree Rana; Karyn Austin; James D Baleja; Nga Nguyen; Andrew Bohm; Lidija Covic; Athan Kuliopulos
Journal:  J Biol Chem       Date:  2016-09-09       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.